The cone dysfunction syndromes

British Journal of Ophthalmology

Volumn 100, Issue 1, 2016, Pages 115-121

  Aboshiha, Jonathan ^a,b   Dubis, Adam M ^a,b   Carroll, Joseph ^c   Hardcastle, Alison J ^a,b   Michaelides, Michel ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLUE CONE MONOCHROMATISM; BORNHOLM EYE DISEASE; BRADYOPSIA; CNGA3 GENE; CNGB3 GENE; COLOR BLINDNESS; COMPLETE ACHROMATOPSIA; CONE DYSFUNCTION SYNDROME; ELECTRORETINOGRAPHY; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GNAT2 GENE; HUMAN; INCOMPLETE ACHROMATOPSIA; MUTATIONAL ANALYSIS; NONHUMAN; OLIGOCONE TRICHROMACY; ONSET AGE; OPHTHALMOSCOPY; OPN1LW GENE; OPN1MW GENE; OPTICS SCANNING LIGHT OPHTHALMOSCOPY; PHENOTYPE; PRIORITY JOURNAL; REFRACTION ERROR; RETINA DISEASE; REVIEW; RGS9 GENE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; COLOR VISION DEFECTS; GENETICS; PATHOLOGY; RETINA CONE; RETINAL DISEASES; SYNDROME;

COLOR VISION DEFECTS; GENOTYPE; HUMANS; PHENOTYPE; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL DISEASES; SYNDROME;

EID: 84952638972     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306505     Document Type: Review

References (100)

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014;4:e004015.
2. Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. Br J Ophthalmol 2004;88:291-7.
3. Michaelides M, Hardcastle AJ, Hunt DM, et al. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol 2006;51:232-58.
4. Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med 2013;15:65-77.
5. Sharpe LT, Stockman A, Jagle H, et al. Opsin genes, cone photopigments and colour blindness. In: Gegenfurtner KR, Sharpe LT, eds. Color vision: from genes to perception. 1st edn. Cambridge: Cambridge University Press, 2001:48-52.
6. Simon GB, Abraham F, Melamed S. Pingelapese achromatopsia: correlation between paradoxical pupillary response and clinical features. Br J Ophthalmol 2004;88:223-5.
7. Andréasson S, Tornqvist K. Electroretinograms in patients with achromatopsia. Acta Ophthalmologica 1991;69:711-16.
8. Kohl S, Baumann B, Broghammer M, et al. Mutations in the CNGB3 gene encoding the β-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 2000;9:2107-16.
9. Hess R, Nordby K. Spatial and temporal limits of vision in the achromat. J Physiol 1986;371:365-85.
10. Simunovic M, Moore A. The cone dystrophies. Eye 1998;12:553-65.
11. Roosing S, Thiadens AA, Hoyng CB, et al. Causes and consequences of inherited cone disorders. Prog Retin Eye Res 2014;42:1-26.
12. Wissinger B, Jägle H, Kohl S, et al. Human rod monochromacy: linkage analysis and mapping of a cone photoreceptor expressed candidate gene on chromosome 2q11. Genomics 1998;51:325-31.
13. Sundin OH, Yang J-M, Li Y, et al. Genetic basis of total colourblindness among the Pingelapese islanders. Nat Genet 2000;25:289-93.
14. Brody J, Hussels I, Brink E, et al. Hereditary blindness among Pingelapese people of Eastern Caroline islands. Lancet 1970;295:1253-7.
15. Wissinger B, Gamer D, Jägle H, et al. CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Human Genet 2001;69:722-37.
16. Johnson S. Achromatopsia caused by novel mutations in both CNGA3 and CNGB3. J Med Genet 2004;41:20e-20.
17. Kohl S, Varsanyi B, Antunes GA, et al. CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet 2005;13:302-8.
18. Thiadens AA, Slingerland NW, Roosing S, et al. Genetic etiology and clinical consequences of complete and incomplete achromatopsia. Ophthalmology 2009;116:1984-9. e1.
19. Kohl S, Baumann B, Rosenberg T, et al. Mutations in the cone photoreceptor G-Protein α-Subunit Gene GNAT2 in patients with achromatopsia. Am J Human Genet 2002;71:422-5.
20. Chang B, Grau T, Dangel S, et al. A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene. Proc Natl Acad Sci 2009;106:19581-6.
21. Kohl S, Coppieters F, Meire F, et al. A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Human Genet 2012;91:527-32.
22. Grau T, Artemyev NO, Rosenberg T, et al. Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia. Hum Mol Genet 2011;20:719-30.
23. Genead MA, Fishman GA, Rha J, et al. Photoreceptor structure and function in patients with congenital achromatopsia. Invest Ophthalmol Vis Sci 2011;52:7298-308.
24. Sundaram V, Wilde C, Aboshiha J, et al. Retinal structure and function in achromatopsia: implications for gene therapy. Ophthalmology 2014;121:234-45.
25. Barthelmes D, Sutter FK, Kurz-Levin MM, et al. Quantitative analysis of OCT characteristics in patients with achromatopsia and blue-cone monochromatism. Invest Ophthalmol Vis Sci 2006;47:1161-6.
26. Varsányi B, Somfai GM, Lesch B, et al. Optical coherence tomography of the macula in congenital achromatopsia. Invest Ophthalmol Vis Sci 2007;48:2249-53.
27. Thomas MG, Kumar A, Kohl S, et al. High-resolution in vivo imaging in achromatopsia. Ophthalmology 2011;118:882-7.
28. Greenberg JP, Sherman J, Zweifel SA, et al. Spectral-domain optical coherence tomography staging and autofluorescence imaging in achromatopsia. JAMA Ophthalmol 2014;132:437-45.
29. Roorda A, Williams DR. The arrangement of the three cone classes in the living human eye. Nature 1999;397:520-2.
30. Dubra A, Sulai Y, Norris JL, et al. Noninvasive imaging of the human rod photoreceptor mosaic using a confocal adaptive optics scanning ophthalmoscope. Biomed Opt Express 2011;2:1864-76.
31. Carroll J, Choi SS, Williams DR. In vivo imaging of the photoreceptor mosaic of a rod monochromat. Vision Res 2008;48:2564-8.
32. Dubis AM, Cooper RF, Aboshiha J, et al. Genotype-dependent variability in residual cone structure in achromatopsia: towards developing metrics for assessing cone health. Invest Ophthalmol Vis Sci 2014;55:7303-11.
33. Scoles D, Sulai YN, Langlo CS, et al. In vivo imaging of human cone photoreceptor inner segments. Invest Ophthalmol Vis Sci 2014;55:4244-51.
34. Stockman A, Smithson HE, Michaelides M, et al. Residual cone vision without α-transducin. J Vis 2007;7:8.
35. Varsányi B, Wissinger B, Kohl S, et al. Clinical and genetic features of Hungarian achromatopsia patients. Mol Vis 2005;11:996-1001.
36. Thiadens AAHJ, den Hollander AI, Roosing S, et al. Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. Am J Human Genet 2009;85:240-7.
37. Khan NW, Wissinger B, Kohl S, et al. CNGB3 achromatopsia with progressive loss of residual cone function and impaired rod-mediated function. Invest Ophthalmol Vis Sci 2007;48:3864-71.
38. Thiadens AA, Somervuo V, van den Born LI, et al. Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:5952-7.
39. Thomas MG, McLean RJ, Kohl S, et al. Early signs of longitudinal progressive cone photoreceptor degeneration in achromatopsia. Br J Ophthalmol 2012;96:1232-6.
40. Fahim AT, Khan NW, Zahid S, et al. Diagnostic fundus autofluorescence patterns in achromatopsia. Am J Ophthalmol 2013.
41. Aboshiha J, Dubis AM, Cowing J, et al. A prospective longitudinal study of retinal structure and function in achromatopsia. Invest Ophthalmol Vis Sci 2014;55:5733-43.
42. Kelly JP, Crognale MA, Weiss AH. ERGs, cone-isolating VEPs and analytical techniques in children with cone dysfunction syndromes∗. Doc Ophthalmol 2003;106:289-304.
43. Nishiguchi KM, Sandberg MA, Gorji N, et al. Cone cGMP-gated channel mutations and clinical findings in patients with achromatopsia, macular degeneration, and other hereditary cone diseases. Hum Mutat 2005;25:248-58.
44. Moskowitz A, Hansen RM, Akula JD, et al. Rod and rod-driven function in achromatopsia and blue cone monochromatism. Invest Ophthalmol Vis Sci 2009;50:950-8.
45. Simunovic MP, Regan BC, Mollon J. Is color vision deficiency an advantage under scotopic conditions? Invest Ophthalmol Vis Sci 2001;42:3357-64.
46. Aboshiha J, Luong V, Cowing J, et al. Dark-Adaptation Functions in Molecularly Confirmed Achromatopsia and the Implications for Assessment in Retinal Therapy Trials. Invest Ophthalmol Vis Sci 2014;55:6340-9.
47. Cho K-I, Haque M, Wang J, et al. Distinct and atypical intrinsic and extrinsic cell death pathways between photoreceptor cell types upon specific ablation of Ranbp2 in cone photoreceptors. PLoS Genet 2013;9:e1003555.
48. Haverkamp S, Michalakis S, Claes E, et al. Synaptic plasticity in CNGA3-/-mice: cone bipolar cells react on the missing cone input and form ectopic synapses with rods. J Neurosci 2006;26:5248-55.
49. Baseler HA, Brewer AA, Sharpe LT, et al. Reorganization of human cortical maps caused by inherited photoreceptor abnormalities. Nat Neurosci 2002;5:364-70.
50. Alexander JJ, Umino Y, Everhart D, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007;13:685-7.
51. Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010;19:2581-93.
52. Michalakis S, Mühlfriedel R, Tanimoto N, et al. Restoration of cone vision in the CNGA3-/-mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 2010;18:2057-63.
53. Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011;20:3161-75.
54. Wen R, Tao W, Li Y, et al. CNTF and retina. Prog Retin Eye Res 2012;31:136-51.
55. Zein WM, Jeffrey BG, Wiley HE, et al. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci 2014;55:6301-8.
56. Langlo C, Dubis A, Michaelides M, Carroll J. Comment: CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci 2014;56:1505.
57. Smith V, Pokorny J, Newell F. Autosomal recessive incomplete achromatopsia with protan luminosity function. Ophthalmologica 1978;177:197-207.
58. Smith V, Pokorny J, Newell F. Autosomal recessive incomplete achromatopsia with deutan luminosity. Am J Ophthalmol 1979;87:393.
59. Kohl S. Achromatopsia-Rod monochromacy. In Traboulsi E, ed. Genetic Diseases of the Eye. Oxford University Press. Oxford. 2011:402-9.
60. Rosenberg T, Baumann B, Kohl S, et al. Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations. Invest Ophthalmol Vis Sci 2004;45:4256-62.
61. Finn J, Krautwurst D, Schroeder J, et al. Functional co-assembly among subunits o cyclic-nucleotide-activated, nonselective cation channels, and across species from nematode to human. Biophys J 1998;74:1333-45.
62. Nathans J, Piantanida TP, Eddy RL, et al. Molecular genetics of inherited variation in human color vision. Science 1986;232:203-10.
63. Gardner JC, Michaelides M, Holder GE, et al. Blue cone monochromacy: causative mutations and associated phenotypes. Mol Vis 2009;15:876.
64. Weleber RG. Infantile and childhood retinal blindness: a molecular perspective (The Franceschetti Lecture). Ophthalmic Genet 2002;23:71-97.
65. Young R, Price J. Wavelength discrimination deteriorates with illumination in blue cone monochromats. Invest Ophthalmol Vis Sci 1985;26:1543-9.
66. Gouras P, MacKay C. Electroretinographic responses of the short-wavelength-sensitive cones. Invest Ophthalmol Vis Sci 1990;31:1203-9.
67. Nathans J, Davenport CM, Maumenee IH, et al. Molecular genetics of human blue cone monochromacy. Science 1989;245:831-8.
68. Wang Y, Macke JP, Merbs SL, et al. A locus control region adjacent to the human red and green visual pigment genes. Neuron 1992;9:429-40.
69. Ladekjaer-Mikkelsen A-S, Rosenberg T, Jørgensen A. A new mechanism in blue cone monochromatism. Hum Genet 1996;98:403-8.
70. Reyniers E, Van Thienen MN, Meire F, et al. Gene conversion between red and defective green opsin gene in blue cone monochromacy. Genomics 1995;29:323-8.
71. Carroll J, Dubra A, Gardner JC, et al. The effect of cone opsin mutations on retina structure and the integrity of the photoreceptor mosaic. Invest Ophthalmol Vis Sci 2012;53:8006-15.
72. Cideciyan AV, Hufnagel RB, Carroll J, et al. Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther 2013;24:993-1006.
73. Michaelides M, Johnson S, Simunovic M, et al. Blue cone monochromatism: a phenotype and genotype assessment with evidence of progressive loss of cone function in older individuals. Eye 2005;19:2-10.
74. Gardner JC, Liew G, Quan YH, et al. Three different cone opsin gene array mutational mechanisms with genotype-phenotype correlation and functional investigation of cone opsin variants. Hum Mutat 2014;35:1354-62.
75. Mancuso K, Hauswirth WW, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature 2009;461:784-7.
76. Zhang Z, Pang J, Xia F, et al. AAV-mediated gene therapy restores cone function in a rat with an M-cone Opsin deficiency, a model for blue cone monochromacy. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 1403.
77. Van Lith G. General cone dysfunction without achromatopsia. Xth ISCERG Symposium; 1973:175-80.
78. Michaelides M, Holder G, Bradshaw K, et al. Oligocone trichromacy: a rare and unusual cone dysfunction syndrome. Br J Ophthalmol 2004;88:497-500.
79. Andersen MK, Christoffersen NL, Sander B, et al. Oligocone trichromacy: clinical and molecular genetic investigations. Invest Ophthalmol Vis Sci 2010;51:89-95.
80. Keunen J, De Brabandere S, Liem A. Foveal densitometry and color matching in oligocone trichromacy. In: Drum B, ed. Colour Vision Deficiencies XII: Springer, Netherlands, 1995:203-10.
81. Vincent A, Wright T, Billingsley G, et al. Oligocone trichromacy is part of the spectrum of CNGA3-related cone system disorders. Ophthalmic Genet 2011;32:107-13.
82. Reuter P, Koeppen K, Ladewig T, et al. Mutations in CNGA3 impair trafficking or function of cone cyclic nucleotide-gated channels, resulting in achromatopsia. Hum Mutat 2008;29:1228-36.
83. Michaelides M, Rha J, Dees EW, et al. Integrity of the cone photoreceptor mosaic in oligocone trichromacy. Invest Ophthalmol Vis Sci 2011;52:4757-64.
84. Nishiguchi K, Sandberg M, Kooijman A, et al. Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. Nature 2004;427:75-8.
85. Michaelides M, Li Z, Rana NA, et al. Novel mutations and electrophysiologic findings in RGS9-and R9AP-associated retinal dysfunction (Bradyopsia). Ophthalmology 2010;117:120-7.
86. Kooijman A, Houtman A, Damhof A, et al. Prolonged electro-retinal response suppression (PERRS) in patients with stationary subnormal visual acuity and photophobia. Doc Ophthalmol 1991;78:245-54.
87. Liyanage SE, Cooper RF, Ba-Abbad R, et al. Imaging Photoreceptor Structure in Subjects with R9AP-and RGS9-associated Retinal Dysfunction (Bradyopsia). Invest Ophthalmol Vis Sci 2014;55:E-Abstract 259.
88. Cheng JY, Luu CD, Yong VH, et al. Bradyopsia in an Asian man. Arch Ophthalmol 2007;125:1138-40.
89. Hartong DT, Pott J-WR, Kooijman AC. Six patients with bradyopsia (slow vision): clinical features and course of the disease. Ophthalmology 2007;114:2323-31.
90. Cowan CW, Fariss RN, Sokal I, et al. High expression levels in cones of RGS9, the predominant GTPase accelerating protein of rods. Proc Natl Acad Sci 1998;95:5351-6.
91. Lishko PV, Martemyanov KA, Hopp JA, et al. Specific binding of RGS9-Gβ5L to protein anchor in photoreceptor membranes greatly enhances its catalytic activity. J Biol Chem 2002;277:24376-81.
92. Haim M, Fledelius H. X-linked myopia in danish family. Acta Ophthalmol 1988;66:450-6.
93. Schwartz M, Haim M, Skarsholm D. X-linked myopia: Bornholm Eye Disease. Clin Genet 1990;38:281-6.
94. Young TL, Deeb SS, Ronan SM, et al. X-linked high myopia associated with cone dysfunction. Arch Ophthalmol 2004;122:897-908.
95. Michaelides M, Johnson S, Bradshaw K, et al. X-linked cone dysfunction syndrome with myopia and protanopia. Ophthalmology 2005;112:1448-54.
96. McClements M, Davies WI, Michaelides M, et al. Variations in opsin coding sequences cause X-linked cone dysfunction syndrome with myopia and dichromacy. Invest Ophthalmol Vis Sci 2013;54:1361-9.
97. Ueyama H, Muraki-Oda S, Yamade S, et al. Unique haplotype in exon 3 of cone opsin mRNA affects splicing of its precursor, leading to congenital color vision defect. Biochem Biophys Res Commun 2012;424:152-7.
98. Carroll J, Neitz J, Neitz M. Estimates of L:M cone ratio from ERG flicker photometry and genetics. J Vis 2002;2:531-42.
99. Neitz J, Wagner-Schuman M, Dubra A, et al. Cone Mosaic Disruption Caused by L/M Opsin Mutations in Bornholm Eye Disease. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 4896.
100. Schornack MM, Brown WL, Siemsen DW. The use of tinted contact lenses in the management of achromatopsia. Optometry 2007;78:17-22.